ANI Pharmaceuticals Income Before Tax Over Time
| ANIP Stock | USD 57.23 2.16 3.64% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out ANI Pharmaceuticals Performance and ANI Pharmaceuticals Correlation. ANI |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ANI Pharmaceuticals. If investors know ANI will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ANI Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 13.824 | Earnings Share (0.47) | Revenue Per Share 28.915 | Quarterly Revenue Growth 0.125 | Return On Assets 0.0125 |
The market value of ANI Pharmaceuticals is measured differently than its book value, which is the value of ANI that is recorded on the company's balance sheet. Investors also form their own opinion of ANI Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is ANI Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ANI Pharmaceuticals' market value can be influenced by many factors that don't directly affect ANI Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ANI Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if ANI Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ANI Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Income Before Tax Analysis
Compare ANI Pharmaceuticals and related stocks such as Eagle Pharmaceuticals, Phibro Animal Health, and Deciphera Pharmaceuticals Income Before Tax Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PAHC | 14 M | 13.1 M | 17.8 M | 6.3 M | 78.8 M | 76.8 M | 80.5 M | 88.1 M | 71.5 M | 55.5 M | 66.5 M | 72.3 M | 54.1 M | 10.9 M | 10.4 M |
| PBH | 2.4 M | 61.2 M | 106 M | 101.7 M | 127.5 M | 157.2 M | 110.8 M | 107.1 M | (38.1 M) | 191.2 M | 204.1 M | 262.5 M | (93.9 M) | 276 M | 289.8 M |
| ALKS | (8.1 M) | (114.4 M) | 35.4 M | 5.4 M | (14 M) | (224 M) | (214.4 M) | (143.3 M) | (127 M) | (197.1 M) | (96.5 M) | (39.3 M) | (167.3 M) | 421.5 M | 442.6 M |
| RDY | 15.3 M | 18.5 B | 21.7 B | 26.6 B | 28.2 B | 27.1 B | 14.7 B | 14.3 B | 22.4 B | 18 B | 28.3 B | 32.3 B | 60.5 B | 71.9 B | 75.5 B |
| COLL | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (17.9 M) | (27.3 M) | (94.2 M) | (74.9 M) | (39.1 M) | (22.7 M) | 27.6 M | (3.4 M) | (28.8 M) | 75.7 M | 79.5 M |
| PCRX | (45.6 M) | (43.3 M) | (52.3 M) | (64.4 M) | (13.5 M) | 2.1 M | (37.8 M) | (42.5 M) | (425 K) | (10.7 M) | 20.1 M | 56.4 M | 13.3 M | 61.7 M | 64.8 M |
| PROC | (10 M) | (10 M) | (10 M) | (10 M) | (10 M) | (10 M) | (10 M) | (10 M) | (10 M) | (10 M) | 849 K | (87.2 M) | 52.7 M | 67.7 M | 71.1 M |
| NBIX | 6.1 M | 37.6 M | 5 M | (46.1 M) | (60.5 M) | (88.9 M) | (141.1 M) | (142.5 M) | 21.8 M | 46.5 M | 106.7 M | 101.4 M | 213.9 M | 332.1 M | 348.7 M |
| AMPH | (31.9 M) | (31.9 M) | 25.9 M | 17.2 M | (18.1 M) | (10.4 M) | 14.9 M | 1.6 M | (9.9 M) | 60.2 M | 4.6 M | 84.1 M | 116 M | 171.4 M | 179.9 M |
| IRWD | (53.2 M) | (64.8 M) | (72.6 M) | (272.8 M) | (189.6 M) | (142.7 M) | (81.7 M) | (116.9 M) | (282.4 M) | 58.9 M | 108.9 M | 200.7 M | 252.4 M | (948.1 M) | (900.7 M) |
| INCR | (12.5 M) | (6.8 M) | 43.4 M | (6.6 M) | (3.8 M) | (1.9 M) | 265.4 K | (5.3 M) | (12.8 M) | (3.7 M) | (38.3 M) | 18.7 M | 43.8 M | (61.3 M) | (58.2 M) |
ANI Pharmaceuticals and related stocks such as Eagle Pharmaceuticals, Phibro Animal Health, and Deciphera Pharmaceuticals Income Before Tax description
Income Before Tax which can also be referred as pre-tax income is reported on ANI Pharmaceuticals income statement and is an important metric when analyzing ANI Pharmaceuticals profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.My Equities
My Current Equities and Potential Positions
| ANI Pharmaceuticals | ANIP |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Minnesota; U.S.A |
| Exchange | NASDAQ Exchange |
USD 57.23
Additional Tools for ANI Stock Analysis
When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.